ABL-SA

ABL-SA (also known as ABL201) is a bispecific monoclonal antibody developed by ABL Bio for the treatment of Staphylococcus aureus infections, including methicillin-resistant Staphylococcus aureus (MRSA). The antibody is engineered to simultaneously target and neutralize two critical virulence factors: Alpha-hemolysin (Hla), a pore-forming toxin that causes host cell lysis and tissue damage, and Clumping factor A (ClfA), a surface protein that facilitates bacterial adhesion to host tissues and fibrinogen. By inhibiting these mechanisms, ABL-SA aims to reduce bacterial colonization, prevent toxin-mediated damage, and enhance the host immune system's ability to clear the infection. It has been investigated in preclinical models for severe systemic infections such as bacteremia and pneumonia.

Other names

Anti-S. aureus bispecific antibody